FACULTY
Jonathan Corren, MD
Clinical Faculty Member
David Geffen School of Medicine at UCLA
Private Practice in Allergy and Immunology
Los Angeles, CA
PROGRAM OVERVIEW
This enduring activity focuses on understanding the etiopathologies of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) to optimize the use of medical, surgical, and novel biologic therapies in the management of CRSwNP through assessment of clinical evidence. Patient-specific treatment selection strategies aimed at reducing overall disease burden and optimizing patient quality of life will also be thoroughly addressed. Listen to an expert discuss the immunology behind the disease, the different treatment options commonly employed as initial therapy, the various biologics available to manage difficult-to-treat or recurrent disease, how they work, and what patient-specific considerations might be taken into account when selecting from the various therapies available.
TARGET AUDIENCE
This educational activity is designed to meet the identified needs of allergists, immunologists, otolaryngologists, and other members of the multidisciplinary team to ensure an up-to-date understanding of the latest data in management of CRSwNP.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Identify patient-centered, multidisciplinary communication strategies to better understand disease impact on quality of life (QoL)
- Describe the etiopathogenesis of CRSwNP
- Explain the latest clinical evidence for novel and investigational therapies for the management of CRSwNP
- Outline treatment selection strategies that are patient-specific with the goal of improving outcomes
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Jonathan Corren, MD | Discloses that he has received consulting fees from AstraZeneca and Sanofi/Regeneron. He has served on the speakers’ bureau from AstraZeneca, GlaxoSmithKlein, and Sanofi/Regeneron. He has commercial interest in AstraZeneca and Sanofi/Regeneron. In addition, he has conducted contracted research for AstraZeneca, Novartis, Pulmatrix, and Sanofi/Regeneron. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Shannon Mutch MS, RN, OCN, has nothing to disclose.
- Michael Milano, MD, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Michael L. Andria, PharmD, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
- Daniel Dasilva, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.
- Ana Maria Albino, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Jessica Feygin-Samuels, Associate Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: March 11, 2024
EXPIRATION DATE: March 11, 2025
Copyright ©2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
